Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model

@article{Singer2005TargetingBW,
  title={Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model},
  author={Oded Singer and Robert A. Marr and Edward M. Rockenstein and Leslie A. Crews and Nicole G. Coufal and Fred H. Gage and Inder M. Verma and Eliezer Masliah},
  journal={Nature Neuroscience},
  year={2005},
  volume={8},
  pages={1343-1349}
}
In Alzheimer disease, increased β-secretase (BACE1) activity has been associated with neurodegeneration and accumulation of amyloid precursor protein (APP) products. Thus, inactivation of BACE1 could be important in the treatment of Alzheimer disease. In this study, we found that lowering BACE1 levels using lentiviral vectors expressing siRNAs targeting BACE1 reduced amyloid production and the neurodegenerative and behavioral deficits in APP transgenic mice, a model of Alzheimer disease. Our… Expand
Lentivirus-expressed siRNA vectors against Alzheimer disease.
TLDR
It is demonstrated that decreasing the expression of Bace1 via lentiviral vector delivery of BACE1 siRNA has the potential for significantly reducing the cleavage of APP, accumulation of these products, and consequent neurodegeneration. Expand
Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.
TLDR
The successful use of an allele-specific RNA interference (RNAi) approach targeting the Swedish variant of APP (APPsw) in a transgenic mouse model of AD supports the development of allele- specific RNAi strategies to treat familial AD and other dominantly inherited neurodegenerative diseases. Expand
Evaluation of BACE1 Silencing in Cellular Models
TLDR
SiRNAs active in human, mouse, and rat cell models were shown to diminish the level of BACE1, the major enzyme participating in generation of toxic amyloid-beta peptides in Alzheimer's disease brains. Expand
BACE1 Inhibitors: Attractive Therapeutics for Alzheimer’s Disease
TLDR
The current knowledge and the molecular and physiological challenges associated with Bace1 inhibition are reviewed and alternatives to the direct targeting of CNS BACE1 to prevent AD are proposed, as well as methods to measure the therapeutic efficacy of B ACE1 inhibition. Expand
BACE1 gene deletion: Impact on behavioral function in a model of Alzheimer's disease
TLDR
Results suggest that while excess Abeta is functionally pathological, BACE1-mediated processing of APP and other substrates play a role in "normal" learning, memory and sensorimotor processes. Expand
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice
TLDR
It is demonstrated that genetic deletion of the beta-secretase (BACE1) not only abrogates Abeta generation and blocks amyloid deposition but also prevents neuron loss found in the cerebral cortex and subiculum, brain regions manifesting the most severe amyloidsosis in 5XFAD mice. Expand
SIRNA GENE THERAPY FOR ALZHEIMER'S DISEASE TARGETING APP GENE
TLDR
The vector pAZLDC1 was newly designed for silencing the APP gene which may act as a foundation stone in the search of an efficient therapeutic approach for treatment of Alzheimer’s disease. Expand
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild‐type mice 2
TLDR
The feasibility of Abeta reduction through BACE1 inhibition under physiological conditions is confirmed, and studies using the new ELISA in non‐transgenic mice provide more accurate evaluation of AbETA‐reducing strategies than was previously feasible. Expand
BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status
TLDR
Potential side effects of BACE1 inhibitors that will require further evaluation to provide a safe therapy for AD are alerted. Expand
BACE 1 GENE AS A POTENTIAL CANDIDATE FOR siRNA GENE THERAPY AGAINST ALZHEIMER ’ S DISEASE
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of the brain. The focus of the present study is to design a curative therapeutic approach for Alzheimer’s disease, based on theExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 68 REFERENCES
Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice
TLDR
It is shown that unilateral intracerebral injection of Lenti-Nep reduced amyloid-β deposits by half relative to the untreated side and suggested that gene transfer approaches might have potential for the development of alternative therapies for Alzheimer's disease. Expand
High β-Secretase Activity Elicits Neurodegeneration in Transgenic Mice Despite Reductions in Amyloid-β Levels
TLDR
It is demonstrated that high levels of BACE1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo, and this pathogenic pathway involves the accumulation of APP C-terminal fragments but does not depend on increased production of human Aβ. Expand
High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease.
TLDR
It is demonstrated that high levels of BACE1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo, and this pathogenic pathway involves the accumulation of APP C-terminal fragments but does not depend on increased production of human Abeta. Expand
BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease
TLDR
It is shown that BACE1 null mice engineered to overexpress human APP (BACE1(-/-).Tg2576(+)) are rescued from Abeta-dependent hippocampal memory deficits, demonstrating that lower Abeta levels are beneficial for AD-associated memory impairments and validating Bace1 as a therapeutic target for AD. Expand
BACE1 Suppression by RNA Interference in Primary Cortical Neurons*
TLDR
The results indicate that BACE1 siRNA specifically impacts on β-cleavage of APP and may be a potential therapeutic approach for treating AD. Expand
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
TLDR
The findings that BACE is the primary beta- secretase activity in brain and that loss of beta-secretase activity produces no profound phenotypic defects with a concomitant reduction in beta-amyloid peptide clearly indicate that Bace is an excellent therapeutic target for treatment of AD. Expand
The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance
TLDR
Results suggest that Cerebrolysin treatment might have beneficial effects in patients with cognitive impairment by reducing Aβ accumulation and promoting the preservation of synaptic terminals. Expand
Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles.
TLDR
Using tau and APP as model targets, an efficient method for producing small interfering RNA (siRNA) against essentially any targeted region of a gene is described and guiding principles for the production of allele-specific siRNAs are suggested. Expand
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
TLDR
Upon intracerebellar injection, recombinant adeno-associated virus vectors expressing short hairpin RNAs profoundly improved motor coordination, restored cerebellar morphology and resolved characteristic ataxin-1 inclusions in Purkinje cells of SCA1 mice, demonstrating in vivo the potential use of RNAi as therapy for dominant neurodegenerative disease. Expand
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
TLDR
The levels of the amyloid precursor protein C‐terminal fragment produced by β‐secretase to be increased by nearly twofold in Alzheimer's disease cortex is found. Expand
...
1
2
3
4
5
...